Introduction
A number of bacterial, viral and parasitic pathogens have been shown to express surface proteins that interact with specific glycoconjugates on cell surfaces [ 1, 2] . Pioneer studies on haemagglutinating Escherichia coli and other enteric organisms, and haemagglutinin and sialidases of influenza virus, were published several decades ago. Development of specific glycoconjugate receptor analogues against influenza virus, as well as receptor analogues to gal-1 -4pgal conjugate carbohydrate receptor structures of the blood group antigen for uropathogenic E. coli, has encouraged much later research to define specific microbial surface haemagglutinins and other carbohydrate-binding proteins, generally called lectins, as targets for antiadhesion thereapy.
Glycosaminoglycans (GAGs), i.e., heparan sulphate, dermatan sulphate, chondroitin sulphates, keratin sulphate, heparin and other sulphated molecules, and hyaluronic acid which is unsulphated, are found ubiquitously in the human body. They form a major part of the extracellular matrix (ECM). Heparan sulphate is expressed on the surface of eukaryotic cells and heparin is present in mast cells. Cell surface GAG molecules mediate many cellular processes. Among these are cell-ECM adhesion [3, 4] , cell migration and growth, and various cellto-cell signalling processes [ 1, 51. They also bind growth factors, growth factor-binding proteins, apolipoprotein, proteases and protease inhibitors [6] . Many pathogenic bacteria, viruses, fungi and parasites have learnt to use cell surface glycolipids, glycoproteins and GAGs as receptor molecules for cell attachment, as well as eukaryotic cell invasion and intercellular migration processes. These interactions usually involve specific surface proteins of micro-organisms, named adhesins. As these proteins commonly interact with specific carbohydrate structures on glycoconjugates, they can also be defined as microbial surface lectins that enable the microbes to initiate an infectious process.
Microbial binding to glycolipids and glycoproteins by specific surface lectins, often with haemagglutinating (HA) activity, has been discussed extensively elsewhere [7] . In contrast, binding to cell surface and ECM GAGS has been studied poorly, despite the fact that well-defined interactions with heparan sulphate and c hondroi t in-4-sul p hat e were described many years ago for herpes simplex virus [8] and, more recently, for bacterial pathogens such as Helicobacter pylori [9] , Staphylococcus aureus [ 101 and Streptococcus pyogenes or group A streptococci [ 111 (Table 1 ). Early observations showed that Tvpanosoma cruzi possessed a cell-surface protein that bound to specific heparan sulphate molecules on macrophages. This triggers cell uptake and adhesion to specific ECM molecules involved in phagocytic processes, such as fibronectin (Fn) [12] . Another important human parasite, Plasmodium falciparum, was shown to bind two specific ECM molecules, Fn and thrombospondin (TSP), as well as heparin, heparan sulphate and chondroitin sulphate A [13-171. In 1996 and 1997, two intracellular pathogens, Mycobacterium tuberculosis and Listeria monocytogenes, were shown to bind heparan sulphate by specific surface molecules [18, 191 , and the first experimental data were presented to prove that binding to this GAG molecule on macrophages and other cells may trigger cellular uptake [19] .
This review focuses on GAG molecules as adhesion receptors for bacteria, viruses and parasites. As GAGstructures are terminal carbohydrate structures linked to protein cores buried in cell membranes in the ECM, as well as in intracellular granulae, specific microbial GAG-binding proteins (GAGBPs) may be involved in cell adhesion, cell uptake and invasion, and in various intercellular and ECM tissue penetration processes [ 11. Interestingly, two bacterial pathogens, H. pylori and Neisseria gonorrhoeae, bind heparin and heparan sulphate [9, 20] in the same way as some pathogens commonly defined as extracellular microbes, i.e., Borrelia spp. and Treponema pallidum [2 1,221. These pathogens may adapt to multiply in the ECM in various body tissues, without triggering uptake by macrophages and other phagocytes, or by other cells. From current knowledge of the most extensively studied GAG-microbe interactions, an initial cellbinding event must be followed by binding to other cell-surface glycoconjugates, most likely specific cellsurface glycolipids, as in the case of herpes simplex and related viruses such as cytomegalovirus (CMV) and dengue virus [23] . One recent report suggests that prions may also use heparan sulphate or other similar cell surface and ECM molecules, such as laminin, in cellular interactions in the brain and other body tissues. This information should stimulate much research on the interplay of possible multiple glycoconjugate microbial adhesion events in determining the first and later stages of various viral, bacterial and parasitic infections [24] .
Glycosaminoglycan and proteoglycan chemistry
Several cell membrane proteoglycans have single transmembrane-spanning domains in a type I orientation [25] , with syndecan-l as the prototype. The members of this family of so-called core proteins are fibroglycan-syndecan and ryudocan (Table 2) . Each of these molecules has conserved attachment sites for 3-5 GAG chains. The syndecans exemplify hybrid proteoglycans as they contain mixtures of the two major types of GAG chains found in animal cells, heparan sulphate and chondroitin-4 sulphate. Other cell-surface proteoglycans include hybrid molecules of P-glycan and a spliced form of the CD 44 molecule (epiglycan), chondroitin sulphate proteoglycans and thrombomodulin [I] . The other major family of proteoglycans is named glypicans, as the members possess glycosylphosphatidylinositol membrane-spanning domains such as glypican-1 and K glypican. Unlike the syndicans, the glypicans appear to contain only heparan sulphate chains. Interestingly, expression of these proteoglycans . In both heparin and heparan sulphate, these sulphate residues occur at the amino groups and the C-6 hydroxyl groups of glycosamine residues, at C-2 of iduronic acid and glucuronic acid, and sometimes at the C-3 OH position of glycosamine residues. Various modifications occur to a greater extent in heparin than in heparan sulphate (e.g., >80% of glycosamine residues are N-sulphated compared to <60% of heparan sulphate). The content of iduronic acid and the degree of 0-sulphation also vary more in heparin. 
Glycosaminoglycan binding in microbial adhesion to mucosal surfaces
Examination of the binding properties of 125 I-heparan sulphate with sialoglycoconjugates, and haemagglutina- With Mycoplasma pneumoniae, dextran sulphate has been shown to inhibit adhesion to pulmonary epithelium [49] , suggesting that binding of dextran sulphate would mediate adhesion. This has not been followed up. Klotz and Smith [37] were the fist to describe the influence of various GAG molecules on the binding of C. albicans to different ECM proteins. In a series of experiments it was shown that GAG molecules and dextran sulphate bind primarily to heparin-binding ECM molecules such as Fn and, in so doing, cover or mask potential binding ligands in ECM for C. albicans. Dextran sulphate, which is more highly charged than heparin, did not show any effect, indicating that specific interactions occur between heparin or heparan sulphate and subendothelial ECM [37] . However, a GAG-binding protein has not yet been identified in C. albicans.
Bergey and Stinson [ 1 11 described heparin-inhibitable binding to ECM basal membranes of Str. pyogenes and Str. mutans, and proposed that these binding properties were possible virulence traits in specific infections caused by these pathogens. Heart tissue GAG binding could target the attachment of microbes to heart valves in subacute endocarditis, and binding to the basement membrane in kidneys could be involved in glomerulonephritis following Str. pyogenes infections. These early observations, as well as the observation that GAG-like molecules and, possibly sulphated glycolipids bind to organisms grown in brain heart infusion broth encouraged a comparison of the influence of various media and culture conditions on expression of GAG binding. GAG-binding proteins of H. pylori were expressed optimally in GabCamp broth, unlike production of sialic acid-specific and other H. pylori HAS and Lewis-binding proteins which were expressed optimally on solid media such as GabCamp agar [50, 51] . The opacity factor or Opa adhesin of N. gonorrhoeae was expressed when the bacteria were grown in polysaccharide-free medium [52] . Growth in serum or on agar resulted in coverage of the bacterial cells with polysaccharides binding to the Opa adhesin. For the recently described GAGBPs of M. tuberculosis [18] and L. monocytogenes [19], [54, 551, but specific biovariants of the trachoma-Lymphogranuloma venereum (LGV) group also express neuraminidase-sensitive eukaryotic cell receptors [56] . However, as heparin inhibits cell binding of all chlamydiae, the basic mechanism of cell attachment is likely to be common in the genus, thus including 'new' pathogens such as Ch. pneumoniae or TWAR [56] . In brief, cell attachment and infectivity is trypsin-sensitive and is reduced following mild heat treatment of elementary bodies, but cell invasion by these organisms probably also involves other glycoconjugate receptors [ 571. Moreover, chlamydiae seem to synthesise heparan sulphate molecules, suggesting a complex interplay of GAG-binding proteins or receptors and GAG molecules in early cell recognition events with this pathogenic prokaryotic intracellular organism [35] . It is likely that this is followed by interaction with other eukaryotic cell receptors, as proposed for heparan sulphate-binding viruses like herpes simplex, which may involve secondary binding to fibroblast growth factor receptors to trigger cell uptake and intracellular multiplication ~2,581.
Apart from mediating epithelial adhesion, the 28-kDa HEBP of M. tuberculosis and M. bovis mediates mycobacterial aggregation which, per se, may promote virulence by formation of microcolonies in vivo at the site of adhesion [18] . However, more in-vitro studies in serum-containing and serum-free systems with macrophages are necessary to define a possible interplay of GAG molecules with individual pathogens. Such studies will form a basis for deciding if GAG molecules such as heparin and various 'heparinoids' can be used in combination with other glycoconjugates to block uptake into macrophages, other professional phagocytes and other target cells in pathogenesis. Such cells include the human gastric epithelium for H. pylori, and the urogenital and respiratory tract epithelium for chlamydiae, Bord. pertussis and Hue. influenzae. Another genital tract pathogen, N. gonorrhoeae, has been found to interact with various cell types in heparin inhibition experiments [52] . N. gonorrhoeae expressing Opa A, C, F, G and H [20] absorb various exogenous polyanions such as nucleic acids and heparin. As heparin was found to increase the serum resistance of Opa+ compared with Opa-gonococci, it has been proposed that cellular GAG molecules shed in genital fluid during infection may bind to Opat gonococci and protect them from phagocytosis, in the same way that sialylated capsules can protect E. coli K1 strains from phagocytosis in neonatal septicaemia and sialylated lipopolysaccharides can protect gonococci from phagocytosis [52] .
Possible role of glycosaminoglycan binding in intracellular survival

Other biological effects
A number of adhesins to epithelial cells have been identified in Yersinia enterocolitica, including YadA, Ail and Inv [64] . The Yop virulon is a plasmid-encoded virulence apparatus which confers on Yersinia the ability to secrete a number of proteins that inhibit host defence mechanisms and enhance intracellular survival [65] . LcrG has been identified as a regulatory Whether GAG binding may promote invasion of eukaryotic cells by microbes has been a matter of controversy. For herpes simplex, gpB binding of heparan sulphate appears to mediate adhesion, as well as virus-cell fusion and syncytium formation [68] , and the cell surface protein ActA of L. monocytogenes mediates both adhesion to professional and nonprofessional phagocytes and internalisation by invasion through the basolateral surface of epithelial cells [69] . For other microbes, it may be more appropriate to refer to GAG adhesion as an initial, sometimes irreversible, adhesion leading to tight adherence, internalisation and inflammatory responses which may be mediated by activation of other receptor molecules [70] .
At least three growth factors require heparin for activation. These are acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF). The finding that S. aureus and coagulase-negative staphylococci, as well as H. pylori, can bind bFGF and PDGF specifically [71, 721 may indicate that binding of heparin or growth factors by pathogens can interfere with wound healing in various organs. In addition, it has been suggested that heparan sulphate-growth factor interactions target Pseudomonas aeruginosa exotoxin to susceptible cells [73] .
It can be speculated that GAG binding of rather low specificity occurs with surface proteins expressing basic amino acid-rich surface domains, followed by interactions with various acidic molecules in body secretions and serum, and that this may be important in creating 'disguised' organisms. Furthermore, surface domains may express proteins rich in hydrophobic domains ('hydrophobins') of importance for the pathogen to evade a strong immune response [74] . Thus, studies on gonococci, H. pylori and other GAGbinding pathogens seem to be of great importance because GAGBPs, as mucosal epithelium adhesins, are vaccine antigen candidates, a concept that would also target molecules besides various surface lectins and [72] . Finally, GAG molecules are associated with cell release and ECM association of various chemokines and cytokines such as interleukin-8 (IL-8) and RANTES (Table 6) , suggesting a role for GAG-like molecules in allergy and chronic mucosal surface inflammation in various organs. This is of relevance for H. pylori-induced type B gastritis, ulcerative colitis and other forms of inflammatory bowel disease.
Reports of positive results with local heparin treatment on the healing process in the rectal mucosa of patients with ulcerative colitis suggest that further studies are warranted on the role of tissue GAG molecules in the normal gastrointestinal tract and inflamed mucosa [85] . Similarly, in the oral cavity, microbes involved in chronic periodontal disease, such as Prevotella spp. and Porphyromonas gingivalis, have been shown to bind specific ECM molecules, but have not yet been investigated for GAG-binding properties [ 861. Reduced expression of heparan sulphate and syndecan-1 has been observed in inflamed human periodontium [87] , which may suggest degradation by adhering microorganisms. If so, this may be an important area for future prophylaxis. It is known that specific binding sequences of microbial lectins and, probably, GAGbinding proteins are usually well-preserved genetically compared with other parts of these ligands. It is probable that genetic characterisation of GAGBPs will define GAG-binding peptides which can also be used as tests for anti-adhesion and anti-infectious effects, analogous to those seen with a Fn 45-kDa fragment (Telios, San Diego, CA, USA) and specific binding domain sequences of staphylococcal FNBPs, used to block C. albicans and S. aureus infections, respectively.
Conclusions
The data showing that a number of microbes may use GAG-binding proteins as adhesins, and the further involvement of GAG molecules during subsequent stages of the infectious process, make GAG molecules promising therapeutic agents. Studies with a Bord. pertussis vaccine based on the fimbrial haemagglutinin (FHA) [88, 891 allow the proposal that GAG-binding proteins are suitable candidates to be incorporated in future vaccines against a number of microbial pathogens, such as chlamydiae, H. pylori, M. tuberculosis, malaria and Leishmania parasites, as well as viruses such as herpes simplex, C M Y and HIV: The use of heparin or other GAG molecules to block adhesion is also attractive, as these substances are produced naturally by the human body. Therefore, allergic reactions and induction of antibodies are rare, although the latter has been reported in patients with renal failure [90] .
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